Literature DB >> 9630322

Bone marrow transplantation and gene therapy for lysosomal storage diseases.

P M Hoogerbrugge1, D Valerio.   

Abstract

Allogeneic bone marrow transplantation with marrow from HLA-identical donors has been used with increasing frequency to treat patients with lysosomal storage diseases. The effects of bone marrow transplantation largely depend on the type and stage of the disease. Generally, 'visceral symptoms' can be largely improved by transplantation, but skeletal lesions are relatively unaffected by transplantation. The effect on neurological symptoms varies.

Entities:  

Mesh:

Year:  1998        PMID: 9630322

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice.

Authors:  Koji O Orii; Jeffrey H Grubb; Carole Vogler; Beth Levy; Yun Tan; Kamelia Markova; Beverly L Davidson; Q Mao; Tadao Orii; Naomi Kondo; William S Sly
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 2.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 3.  Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Authors:  Mark E Haskins
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 4.  Lysosomal storage disorders: emerging therapeutic options require early diagnosis.

Authors:  Peter J Meikle; John J Hopwood
Journal:  Eur J Pediatr       Date:  2003-11-11       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.